Sales gap grows between rival Merck, Bristol cancer therapies

While quarterly sales growth for Bristol-Myers Squibb's cancer immunotherapy Opdivo appear to have plateaued, Merck & Co.'s competing Keytruda has widened its lead in a drug market crucial to both companies' future success.